Preparation method of Relugolix and intermediate compounds

A compound, a technology of hydrazine hydrate, applied in the field of preparation of Relugolix, can solve problems such as being unsuitable for practical production and application, difficult to remove, etc., and achieve the effects of good industrial application prospect, less impurities and mild reaction conditions

CN112745304AInactive Publication Date: 2021-05-04SHANGHAI DUDE MEDICAL SCI & TECH CO LTD
6 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2021-05-04
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a novel preparation method of Relugolix and two novel intermediate compounds. The preparation method comprises the following steps: reducing an existing compound 2 to obtain an amino compound 3, then, carrying out a condensation reaction on the compound 3 and methoxyamine or a salt thereof to obtain a compound 4, and finally, carrying out a cyclization reaction on the compound 4 to obtain a target compound 1. The preparation method is mild in reaction condition and high in reaction controllability; and the method has the advantages of few impurities, no ring-opening and demethylation impurities, good purity, simple post-treatment, high yield, environmental protection, economy and good industrial application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of preparation methods of Relugolix. Background technique

[0002] Relugolix is ​​a gonadotropin-releasing hormone (GnRH) antagonist. The secretion of anterior pituitary hormones is feedback-controlled by peripheral hormones secreted from the target organs of the corresponding hormones and by secretory-regulating hormones from the hypothalamus. It has been confirmed as hypothalamic hormones, including thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH). These secretory-regulating hormones from the hypothalamus express their action through receptors thought to be present in the anterior pituitary. Therefore, GnRH antagonists are expected to prevent or treat anterior pituitary hormone-dependent diseases.

[0003] According to the literature search, the current domestic and foreign reports on the preparation method of Relugolix include literature 1, and the methods described in pate...

Examples

Embodiment 1

[0041] Embodiment 1: the preparation of compound 3-a

[0042]

[0043] Compound 2-a (25.0 g) was put into methanol (200.0 ml), 10% Pd / C (2.5 g) and ammonium formate (4.77 g) were added thereto, and stirred at 50±5° C. for 4 hours. After the reaction was completed, the mother liquor was collected by filtration, and the filter cake was washed with methanol. Raise the mother liquor to 40±5°C and stir for 1 hour, then cool down to 5±5°C, collect crystals by filtration, and wash the filter cake with cold methanol. Drying under reduced pressure gave compound 3-a (22.0 g). yield: 92%, HPLC purity 99.64%.

[0044] 1 H NMR (400MHz, Chloroform-d) δ14.06(d, J=27.0Hz, 1H), 8.56(d, J=9.6Hz, 1H), 7.66(s, 1H), 7.54(d, J=8.1Hz ,2H),7.24(d,J=8.1Hz,2H),7.16–7.07(m,1H),6.98(d,J=9.5Hz,1H),6.73(t,J=7.7Hz,2H),5.03 (s,2H),4.23(s,1H),4.10(s,4H),3.82(s,3H),3.49(s,2H),2.19(s,6H),1.77(s,1H),1.64( s,2H),1.01(s,1H),0.79(t,J=7.1Hz,2H).

Embodiment 2

[0045] Embodiment 2: the preparation of compound 4-a

[0046]

[0047] Compound 3-a (10.0g) and 1,1'-carbonyldiimidazole (5.31g) were put into dichloromethane (40.0ml), and N,N-diisopropylethylamine (4.24g ), and stirred at 20±5° C. for 1-2 hours (hereinafter referred to as reaction mixture A).

[0048]Methoxylamine hydrochloride (13.6eq) was put into dichloromethane (60.0ml), and N,N-diisopropylethylamine (21.18g) was added to the mixture, and stirred at 25±5°C for 1 hour (hereinafter referred to as reaction mixture B). Reaction mixture B was slowly added to reaction mixture A at 0±5°C, and stirred at the same temperature for 1-2 hours. At 0±5°C, add saturated sodium bicarbonate solution to the reaction mixture, stir for 30 minutes and let it stand, and separate the organic phase, wash with saturated sodium bicarbonate solution, distill off the organic solvent under reduced pressure, and wash the residue with ethyl acetate Recrystallized from isopropyl ether to obtain c...

Embodiment 3

[0050] Embodiment 3: preparation compound 1

[0051]

[0052] Compound 4-a (5.0 g) was added to methanol (50.0 ml), sodium methoxide (0.59 g) was added to the mixture, and stirred at room temperature for 2-3 hours. Cool to 0°C or lower and stir for 2-4 hours, collect crystals by filtration, wash the filter cake with methanol and dry under reduced pressure at 50-60°C. The obtained solid was put into tetrahydrofuran, the temperature of the mixture was raised to 60±5°C, and stirred at the same temperature for 1 hour, the mixture was cooled to 0°C, and aged with stirring at the same temperature for 2 hours. The crystals were collected by filtration, and the filter cake was washed with tetrahydrofuran. The filter cake was recrystallized from dimethyl sulfoxide (DMSO) and ethanol to obtain compound 1 (4.25 g). Yield: 93%, HPLC purity 99.68%.